Inflammatory Bowel Disease (IBD) is a chronic disease impacting nearly 1.2 million Americans.1 Developments in treatment, such as biologics, have greatly improved quality of life for patients and advancements in laboratory testing are helping to support diagnosis and optimize therapy. Med lab offers leading expertise and comprehensive testing services to support physicians in the management of IBD patients.
For a detailed look at how Med lab’s IBD test offerings support complete care decisions, see our IBD Test Offerings Matrix in the Related Documents section below.
IBD Treatment Monitoring
Patient response to IBD treatments may be highly variable but new Therapeutic Drug Monitoring (TDM) assays can help optimize therapy using a personalized, patient-specific approach.
Biologics monitoring assays measure both drug concentration and anti-drug antibodies to support improved clinical outcomes and characterize those patients who may have diminished response to therapy.2, 3, 4, 5
- All biologics have variable pharmacokinetics and the potential to induce an antibody-mediated immune response 6,7
- TDM helps optimize dosing and frequency of treatment 2,7,8
- TDM assists in preventing and managing loss of response due to immunogenicity9,10
- TDM has been shown to be cost-effective and may direct more appropriate care.7
|Biologic Drug Name||Med lab Test||LabCorp Test No|
|Infliximab Concentration and Anti-Infliximab Antibody||503870|
|Adalimumab Concentration and Anti-Adalimumab Antibody||503890|
|Vedolizumab Concentration and Anti-Vedolizumab Antibody||504567|
|Golimumab and Anti-Golimumab Antibody||504563|
Patient-specific clinical context must be taken into account when evaluating drug and anti-drug antibody. Serial measurements over time may be helpful. NOTE: These target ranges were those used in landmark studies and do not necessarily transplant into general recommendations for individual patients. Trough collections are recommended in most cases.
Monitoring drug levels for Immunomodulators supports dosing decisions, assessing patient compliance, and determining effectiveness of treatment.
- Utilize during treatment to help reach and maintain therapeutic goal11
- Assists with evaluating unresponsive patients11
- Thiopurine drugs monitoring helps avoid potential toxicity in responsive patients11
- Approximately 30% ñ 40% of RA patients do not adequately respond to methotrexate treatment12
|Drug Name||Med lab Test||Med lab Test No|
TPMT genetic and TPMT activity testing is additionally available to assess dosing prior to Thiopurine treatment, as well as to identify patients who may be at risk for drug toxicity.
A combination of clinical findings, endoscopic, histopathologic, radiologic, and laboratory testing is used to establish the diagnosis of IBD.
Diagnostic challenges arise when clinical presentation is indolent, invasive procedures are not obtainable, or results are inconclusive. Novel serological markers for IBD offer improved sensitivity and specificity to aid in differential diagnosis and provide valuable prognostic information about disease behavior.